In a move likely to up the ante in the emerging Open Source Drug Discovery movement, GlaxoSmithKline have announced the donation of genomic profiling data for over 300 cancer cell lines to the National Cancer Institute’s cancer Bioinformatics Grid (caBIG). According to NCI’s FAQ, caBIG is “an open-source, open-access information network enabling cancer researchers to share tools, data, applications, and technologies according to agreed-upon